Newron Pharmaceuticals S.p.A.
NP5
Classifica tra le azioni
#17730
Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in... Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in Bresso, Milano, with a dedicated team of 24 full-time employees. The company's core mission is the discovery and advancement of innovative pharmaceutical products, particularly focusing on new therapies for Central Nervous System (CNS) disorders and pain management. Among its leading candidates, safinamide is currently undergoing Phase III clinical trials for the treatment of Parkinson's disease. Additionally, ralfinamide is being developed as a potential therapy for neuropathic pain. The firm's pipeline further includes a range of projects at various preclinical and clinical development stages, such as HF0220 for neuroprotection, NW-3509 for schizophrenia, and pruvanserin and sarizotan for other CNS conditions.
Prezzo delle azioni
$10.33
Capitalizzazione di mercato
$211.26M
Variazione (1 giorno)
0.44%
Variazione (1 anno)
-42.21%
Paese
IT
Scambia Newron Pharmaceuticals S.p.A. (NP5)
Categoria
Healthcare
Storico del prezzo dell'azione per Newron Pharmaceuticals S.p.A. (NP5)
Prezzo di chiusura più alto: $10.22 il 2026-10-01
Prezzo di chiusura più basso: $31.91 il 2015-07-01
Prezzo di chiusura più basso: $31.91 il 2015-07-01
Storico del prezzo dell'azione di Newron Pharmaceuticals S.p.A. dal 2015 al 2026
Andamento annuale del prezzo dell'azione
| Anno | Performance |
|---|---|
| 2026 (TTM) | -24.57% |
| 2025 | 182.46% |
| 2024 | 72.12% |
| 2023 | 283.57% |
| 2022 | -24.03% |
| 2021 | -24.86% |
| 2020 | -62.21% |
| 2019 | -18.66% |
| 2018 | -28.88% |
| 2017 | -55.22% |
| 2016 | -5.77% |
| 2015 | 0.00% |
Prezzo dell'azione per aziende simili o concorrenti
| Azienda | Prezzo dell'azione | Variazione 1a% | Il paese |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $766.95 | 9.01% |
CH
|
